Clinuvel 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   7 Trials   127 News 


123»
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Review, Journal:  Treatment Advances in Vitiligo: An Updated Review. (Pubmed Central) -  Mar 21, 2025   
    The advent of treatment modalities like Janus kinase inhibitors, prostaglandin analogues, antioxidants, TNF-? inhibitors, targeted phototherapy, and excimer lasers has revolutionized the therapeutic possibilities, offering a ray of hope to the individuals suffering from this devastating condition.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Trial completion, Trial completion date, Trial primary completion date:  Pharmacokinetics of Afamelanotide in EPP Patients (clinicaltrials.gov) -  Feb 12, 2025   
    P1/2,  N=28, Completed, 
    Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Recruiting --> Completed | Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Jul 2024 --> Oct 2024
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Review, Journal:  Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management. (Pubmed Central) -  Dec 25, 2024   
    Depending on the severity of the liver disease, phlebotomies, exchange transfusions and ultimately liver transplantation with subsequent haematopoietic stem cell transplantation (HSCT) are therapeutic options, whereby multidisciplinary management including porphyria experts is mandatory. Afamelanotide, an alpha-melanocyte-stimulating hormone analogue, is currently the only approved specific treatment that increases pain-free sunlight exposure and quality of life.
  • ||||||||||  Suprefact (buserelin acetate) / Sanofi, Scenesse (afamelanotide) / Clinuvel, Synarel (nafarelin) / Pfizer
    Preclinical, Journal:  Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation. (Pubmed Central) -  Nov 18, 2024   
    The model presented in this manuscript provides valuable insights into the kinetics and mechanism of drug release from PLGA-based solid implants and has demonstrated the potential for optimizing formulation design. The in vitro release model, coupled with physiologically based pharmacokinetic (PBPK) modeling, can predict the in vivo performance of implants and can be used to support bioequivalence studies in a drug development program.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Review, Journal:  Afamelanotide in protoporphyria and other skin diseases: a review. (Pubmed Central) -  May 24, 2024   
    The positive effect of afamelanotide in EPP administered subcutaneously improved tolerance to artificial white light and increased pain-free time spent in direct sunlight. In this review we summarize the possible use of afamelanotide in dermatology, with special emphasis on EPP and encourage including afamelanotide as a treatment option in patient care.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel, Cosentyx (secukinumab) / Novartis, cyclosporine / Generic mfg.
    Review, Journal:  Vitiligo: Pathogenesis and New and Emerging Treatments. (Pubmed Central) -  Dec 27, 2023   
    We reviewed the mechanism of action, efficacy and safety data of phototherapy, afamelanotide, cyclosporine, phosphodiesterase 4 inhibitors, trichloroacetic acid, basic fibroblast growth factor, tumor necrosis factor (TNF) inhibitors, secukinumab, pseudocatalase and janus kinase (JAK) inhibitors. At the moment, there is no clearly outstanding option or fully satisfactory treatment for vitiligo, so it is necessary to keep up the development of new drugs as well as the publication of long-term effectiveness and safety data for existing treatments.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (clinicaltrials.gov) -  Sep 21, 2023   
    P2a,  N=6, Recruiting, 
    At the moment, there is no clearly outstanding option or fully satisfactory treatment for vitiligo, so it is necessary to keep up the development of new drugs as well as the publication of long-term effectiveness and safety data for existing treatments. Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Jun 2024
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Journal:  A gel-forming ?-MSH analog promotes lasting melanogenesis. (Pubmed Central) -  Sep 8, 2023   
    In addition, DDE313 darkened the skin of frogs for >4 weeks, whereas those injected with an equivalent dose of afamelanotide lost the tanning response within a few days. Because self-assembled gels allow sustained activation of melanocortin receptors, further studies of these analogs may allow the development of effective and convenient tanning therapies to prophylactically protect against UV-induced malignant transformation of skin cells in susceptible patients.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel, Vyleesi (bremelanotide) / Palatin Technologies, Imcivree (setmelanotide) / Rhythm Pharma
    Review, Journal:  Targeting the central melanocortin system for the treatment of metabolic disorders. (Pubmed Central) -  Aug 11, 2023   
    These approvals have also renewed excitement in the development of therapeutics targeting the melanocortin system. Here, we review the anatomy and function of the melanocortin system, discuss progress and challenges in developing melanocortin receptor-based therapeutics, and outline potential metabolic and behavioural disorders that could be addressed using pharmacological agents targeting these receptors.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Enrollment closed:  Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP) (clinicaltrials.gov) -  Jul 12, 2023   
    P2a,  N=6, Active, not recruiting, 
    Here, we review the anatomy and function of the melanocortin system, discuss progress and challenges in developing melanocortin receptor-based therapeutics, and outline potential metabolic and behavioural disorders that could be addressed using pharmacological agents targeting these receptors. Recruiting --> Active, not recruiting
  • ||||||||||  ritlecitinib (PF-06651600) / Pfizer, Scenesse (afamelanotide) / Clinuvel, Opzelura (ruxolitinib cream) / Incyte, Maruho
    Review, Journal:  Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. (Pubmed Central) -  Jun 14, 2023   
    Topical ruxolitinib has been registered for vitiligo treatment, whereas other agents as oral ritlecitinib, afamelanotide and latanoprost have been studied in ongoing clinical trials. New highly effective therapeutic strategies may be developed thanks to molecular and genetic studies.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Review, Journal:  Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. (Pubmed Central) -  Mar 16, 2023   
    In addition, increasingly in-depth knowledge about the disease's pathogenetic processes has enabled the development of increasingly targeted therapeutic strategies with high efficacy and fewer side effects. The aim of this paper is, by conducting a narrative review of the literature, to analyze the pathogenesis of vitiligo and the most recent treatments available for this condition.
  • ||||||||||  Scenesse (afamelanotide) / Clinuvel
    Journal:  Discovery of novel N-(1-benzyl-1H-imidazol-2-yl)amide derivatives as melanocortin 1 receptor agonists. (Pubmed Central) -  Nov 15, 2022   
    Therefore, we initiated an investigation aimed at orally available small molecule nonpeptide MC1R agonists. Optimization from the internal hit compound 6a finally resulted in the discovery of N-(1-benzyl-1H-imidazol-2-yl)amide derivative 9g bearing isonipecotinic acid moiety, which demonstrated good MC1R agonistic activity and metabolic stability.